De Luca R, et al. - Authors assessed the effectiveness of Abraxane (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC). Findings suggested a good tolerability and effectiveness of Nab-paclitaxel for patients affected by MPC. An improved tolerability profile, significant pain relief and an upsurge in survival rate were demonstrated by Abraxane. Level of carbohydrate antigen 19-9 was an important predictor of OS, demonstrating a positive correlation; as seen on linear regression analysis between OS and CA 19-9 response.